Clinical trial
Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
NCT01801449 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH · Completed
Key facts
| NCT number | NCT01801449 |
|---|---|
| Title | Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) |
| Official title | A Pilot Open-Label Study of Rilonacept (Arcalyst) in the Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) |
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH |
| Collaborators | National Institutes of Health Clinical Center (CC) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | DIRA |
| Intervention type | Drug |
| Interventions | Rilonacept |
| Enrollment | 6 |
| Start date | Feb 12, 2013 |
| Primary completion | Apr 28, 2016 |
| Completion | Apr 28, 2016 |
| First posted | Feb 28, 2013 |
| Last update posted | Oct 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: